Seattle biotech leads work on coronavirus vaccine candidate

A Seattle-based biotech and partners are developing a vaccine for the coronavirus using RNA-based technology and hope to bring it into human trials this year. The coronavirus began late last year in Wuhan, China, and was first confirmed in the United States in January. So far, there are more than 400 possible cases across 41 states, according to the Centers for Disease Control. Seattle-based HDT BioCorp, which is working with various partners to advance a vaccine to human trials this year, is…